Clinical Trials - Phase IV
Found 3,425 articles
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
- INPULSIS®-ON study indicates safety and efficacy of Ofev® (nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS trials
DoctorLogic ranks 317 out of 5,000 fastest-growing private companies with a total growth of more than 1,500% since its launch.
New technology destroys deadly pathogens and bacteria lurking on hospital surfaces
Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®
BELVIQ did not increase incidence of cardiovascular events in study of 12,000 obese and overweight patients
A report recently published by the National Academies of Sciences, Engineering, and Medicine concluded that institutions and researchers should regularly and carefully evaluate whether and how to provide study results to participants.
Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)
Cannabics Pharmaceuticals Inc. announced that it has concluded its clinical trial held at Rambam Medical Center.
PQ Bypass Reports Positive 12-Month Results for Entirely New Procedure to Treat Extremely Long SFA Lesions in Patients with PAD
DETOUR I Trial Presented during SVS Vascular Annual Meeting 2018 Late Breaking Clinical Trial Session
WCG (WIRB-Copernicus Group) Clinical Services Division Partners with InformedDNA to Help Sponsors Design and Execute More Effective Clinical Trials
Companies join forces to deliver new solutions that optimize genetics in clinical trials in the era of precision medicine.
SetPoint Medical Reports Positive Long-term Results from its Clinical Study of Bioelectronic Medicine to Treat Rheumatoid Arthritis
Results presented at Annual European Congress of Rheumatology highlight strong therapy adherence and significant reduction in rheumatoid arthritis symptoms after 24-months of therapy.
Mallinckrodt Reports Interim Findings Of H.P. Acthar® Gel (Repository Corticotropin Injection) Studies
Rheumatoid Arthritis Phase 4 Clinical Trial Data Recently Presented at the Annual European Congress of Rheumatology
Genentech’s hemophilia treatment Hemlibra continues to demonstrate its efficacy in treating patients. New late-stage data presented at World Federation of Hemophilia 2018 World Congress shows the drug significantly reduced treated bleeds in a broad patient population in two separate studies.
NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access
This first transjugular implantation of the GATE ™ tricuspid valved stent occurred at the Cleveland Clinic in April 2017
LumiThera Inc. presented topline final results from the LIGHTSITE I clinical trial for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System.
Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting
New Phase 4 OSCAR Trial Data Showed that Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% Decreased Acne Lesions Therefore Reducing the Risk of Scars in Moderate-to-Severe Acne Patients
Data Reinforces Importance of Scar Prevention as an Important Goal of Acne Treatment
At the World Medical Innovation Forum, panelists observed that AI can be used to scour old clinical trial data for new applications and possibly take over part of clinical trials in “virtual” models.
Relapsing MS Patients Who Switched to Aubagio® (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies
Patients with relapsing multiple sclerosis who switched to Sanofi Genzyme’s Aubagio® (teriflunomide) from interferon therapy experienced improvements in treatment satisfaction, according to investigational data from two clinical studies.
Wize Pharma Enrolls First Patient in Phase IV Study of LO2A for Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome
Wize Pharma, Inc. announced it has enrolled the first patient in its Phase IV clinical trial in Israel for LO2A in the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome.
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
Erasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy with the CyberKnife® System
New Clinical Trial Evaluates Use of Online-Adaptive Stereotactic Body Radiation Therapy Approach in the Treatment of Oligometastases